blank
blank

ERDERA Clinical Trial Call – Guidelines for Applicants

1:1
These guidelines explain the eligibility rules, submission process and Expression of Interest requirements for the ERDERA Clinical Trial Call.

This document sets out the aim, eligibility criteria, application process, and application instructions for the ERDERA Clinical Trial Call(ECTC).  It also explains the sections required for the Expression of Interest, including project data, project description, the coordinating investigator and sponsor, partners, budget, notes, declarations, submission and data protection.

Acces this publication
blank

publication

ERDERA clinical trial call

Year of publication

2026

Author

European Rare Diseases Research Alliance (ERDERA)

You might also be interested in

2

ERDERA launches Clinical Trial Call 2026 to advance early‑phase clinical trials for rare diseases

ERDERA (the European Rare Diseases Research Alliance) has opened its Clinical Trial Call to support multinational early-phase clinical trials in rare diseases. The call will fund studies designed to generate robust clinical evidence, strengthen regulatory readiness and make rare disease trials more feasible across countries.
ERDERA CTC 2026

ERDERA Clinical Trial Call – Call Text

Call text draft setting out rules, eligibility and staged application process for the ERDERA Clinical Trial Call 2026.
Erdera_IBG_2026_Poster_Social_Media

European Network Conference on Chromatinopathies (EU-CHROMNet)

November 25 - November 27
Photograph of neurons - CC BY-NC-SA 2.0 by Birth Into Being via Flickr.

NCL Foundation launches €200,000 prize to connect rare and common neurodegeneration research

The NCL Foundation has opened the Rare-to-Common Neurodegeneration Impact Prize, a €200,000 research award supporting collaborative projects that connect CLN3 Batten disease research with more common neurodegenerative or age-related disorder

ERDERA's

search form